Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Adjuvant Chemotherapy Clear all
Completed Phase 3 Interventional

Zoledronate, Calcium, and Vitamin D in Preventing Bone Loss in Women Receiving Adjuvant Chemotherapy for Breast Cancer

NCT00022087
View directory record Official record
Conditions
Breast Cancer, Osteoporosis
Interventions
calcium salts, cholecalciferol, zoledronic acid
Dietary Supplement · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
40 Years and older · Female only
Enrollment
439 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
107
States / cities
Arroyo Grande, California • La Jolla, California • Mountain View, California + 80 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Jul 22, 2026, 5:04 PM EDT
Active, not recruiting Phase 2 Interventional

HOT: HIPEC in Ovarian Cancer as Initial Treatment

NCT02124421
View directory record Official record
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma
Interventions
Cytoreductive Surgery (CRS), Adjuvant Chemotherapy, Questionnaire, Hyperthermic intraperitoneal chemotherapy, Carboplatin, Paclitaxel, Cisplatin
Procedure · Drug · Other
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Jul 22, 2026, 5:04 PM EDT
Completed No phase listed Observational

Gene Expression Profiling and Genetic Analysis of Tissues From Patients With Breast Cancer

NCT00899509
View directory record Official record
Conditions
Breast Cancer
Interventions
laboratory biomarker analysis
Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
3
States / cities
Sioux City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Jul 22, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer

NCT00055601
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, fluorouracil, paclitaxel, radiation therapy, Gemcitabine, Radical cystectomy
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2018
U.S. locations
2
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Jul 22, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

NCT00505492
View directory record Official record
Conditions
Uterine Neoplasms
Interventions
Carboplatin, Cisplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Jul 22, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy

NCT00790036
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Everolimus, Everolimus Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
34
States / cities
Chandler, Arizona • Fayetteville, Arkansas • La Jolla, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Jul 22, 2026, 5:04 PM EDT
Terminated Phase 3 Interventional Results available

Chemotherapy or Observation in Treating Patients With Early Stage Non-Small Cell Lung Cancer

NCT00863512
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, docetaxel, gemcitabine hydrochloride, pemetrexed disodium, vinorelbine tartrate, standard follow-up care
Drug · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Burbank, California + 66 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Jul 22, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

Trial of Chemotherapy and Avastin as Treatment for Women With Breast Cancer at High Risk for Relapse

NCT00462865
View directory record Official record
Conditions
Breast Cancer
Interventions
Gemcitabine and Capecitabine and Avastin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
3
States / cities
Albuquerque, New Mexico • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Jul 22, 2026, 5:04 PM EDT
Completed No phase listed Observational

Barriers Associated With Timely Adjuvant Chemotherapy Administration in Patients With Invasive Breast Cancer

NCT04087057
View directory record Official record
Conditions
Invasive Breast Carcinoma
Interventions
Interview, Medical Chart Review, Questionnaire
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 21, 2024 · Synced Jul 22, 2026, 5:04 PM EDT
Active, not recruiting Phase 2 Interventional

Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer

NCT03383094
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Cancer, Cancer of Head and Neck, Cancer, Advanced, Cancer, Metastatic, Tumor, Tumor Recurrence, Tumor Neck, Tumor Metastasis, Oral Cancer, Oropharyngeal Cancer, Oropharynx Cancer, Oropharynx Cancer, Stage III, Oropharynx Cancer, Recurrent, Oropharynx Cancer, Metastatic
Interventions
Pembrolizumab, Radiation therapy, Cisplatin
Drug · Radiation
Lead sponsor
Loren Mell, MD
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
6
States / cities
Tucson, Arizona • La Jolla, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jul 22, 2026, 5:04 PM EDT
Completed Not applicable Interventional Results available

Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

NCT03650803
View directory record Official record
Conditions
Breast Cancer
Interventions
3D MR Fingerprinting scan
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Jul 22, 2026, 5:04 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery

NCT00727441
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
GVAX pancreatic cancer vaccine, cyclophosphamide
Biological · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Jul 22, 2026, 5:04 PM EDT
Withdrawn Not applicable Interventional

Adjuvant High-intensity Interval Training During Chemotherapy in Metastatic Prostate Cancer Patients

NCT05156372
View directory record Official record
Conditions
Prostate Cancer Metastatic, Castrate Resistant Prostate Cancer, Metastatic Prostate Cancer, Metastatic Prostate Adenocarcinoma
Interventions
High Intensity Interval Training
Other
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 25, 2024 · Synced Jul 22, 2026, 5:04 PM EDT
Recruiting Phase 2 Interventional

ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer

NCT06902272
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Circulating Tumor Deoxyribonucleic acid (ctDNA) Assay, Pembrolizumab, Platinum Doublet Chemotherapy
Diagnostic Test · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 5:04 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

NCT03562637
View directory record Official record
Conditions
Triple Negative Breast Cancer
Interventions
adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
Biological · Device · Other
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
18 Years and older
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
12
States / cities
La Jolla, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Jul 22, 2026, 5:04 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation

NCT04030000
View directory record Official record
Conditions
Uterine Carcinoma
Interventions
Paclitaxel/Carboplatin, Pelvic radiation therapy
Drug · Radiation
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 99 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Mar 16, 2023 · Synced Jul 22, 2026, 5:04 PM EDT
Withdrawn Not applicable Interventional

STEREOtactic Radiation and Chemotherapy in Lung Cancer (STEREO)

NCT01300299
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Stereotactic Body Radiation Therapy
Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Jul 22, 2026, 5:04 PM EDT
Active, not recruiting Phase 3 Interventional

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

NCT02954874
View directory record Official record
Conditions
Breast Carcinoma In Situ, Invasive Breast Carcinoma, Stage I Breast Cancer AJCC v7, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Laboratory Biomarker Analysis, Patient Observation, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy
Procedure · Other · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
1,155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
895
States / cities
Birmingham, Alabama • Daphne, Alabama • Mobile, Alabama + 637 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Jul 22, 2026, 5:04 PM EDT
Completed Not applicable Interventional

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

NCT00346125
View directory record Official record
Conditions
Sarcoma
Interventions
pegfilgrastim, doxorubicin hydrochloride, ifosfamide, pegylated liposomal doxorubicin hydrochloride, conventional surgery, fludeoxyglucose F 18
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
16 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
2
States / cities
Baltimore, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2022 · Synced Jul 22, 2026, 5:04 PM EDT
Completed Phase 3 Interventional Results available

Vincristine, Carboplatin, and Etoposide or Observation Only in Treating Patients Who Have Undergone Surgery for Newly Diagnosed Retinoblastoma

NCT00335738
View directory record Official record
Conditions
Intraocular Retinoblastoma
Interventions
liposomal vincristine sulfate, carboplatin, etoposide
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 6 Years
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2020
U.S. locations
48
States / cities
Birmingham, Alabama • Tucson, Arizona • Arcadia, California + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Jul 22, 2026, 5:04 PM EDT
Not listed No phase listed Observational

Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

NCT03691012
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Circulating tumour DNA testing
Diagnostic Test
Lead sponsor
Walter and Eliza Hall Institute of Medical Research
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 5:04 PM EDT
Completed Phase 1 Interventional

Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease

NCT00674791
View directory record Official record
Conditions
Breast Cancer
Interventions
OCPM Immunotherapeutic Vaccine
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 22, 2026, 5:04 PM EDT
Terminated Phase 3 Interventional Results available

Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma

NCT04158141
View directory record Official record
Conditions
Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma, Stage I Pleural Malignant Mesothelioma AJCC v8, Stage IA Pleural Malignant Mesothelioma AJCC v8, Stage IB Pleural Malignant Mesothelioma AJCC v8, Stage II Pleural Malignant Mesothelioma AJCC v8, Stage IIIA Pleural Malignant Mesothelioma AJCC v8
Interventions
Carboplatin, Cisplatin, Decortication, Intensity-Modulated Radiation Therapy, Pemetrexed, Pemetrexed Disodium, Pencil beam scanning proton therapy, Pleurectomy
Drug · Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
12
States / cities
Coral Gables, Florida • Chicago, Illinois • Rochester, Minnesota + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 22, 2026, 5:04 PM EDT
Terminated Phase 2 Interventional Results available

Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy

NCT01251354
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BN83495
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
4
States / cities
Augusta, Georgia • Minneapolis, Minnesota • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2019 · Synced Jul 22, 2026, 5:04 PM EDT